Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

NCT00471965 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

371

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Oxaliplatin + 5-Fluorouracil/Leucovorin
DRUG: Doxorubicin

Sponsor

Sanofi